Efficacy of Laparoscopic Parenchyma-sparing Hepatectomy Using Augmented Reality Navigation Combined With Fluorescence Imaging for Colorectal Liver Metastases: A Retrospective Cohort Study Using Inverse Probability Treatment Weighting Analysis

Xiaojun Zeng; Xinci Li; Wenjun Lin; Junfeng Wang; Chihua Fang; Mingxin Pan; Haisu Tao; Jian Yang

doi:10.1097/JS9.0000000000002193

Efficacy of Laparoscopic Parenchyma-sparing Hepatectomy Using Augmented Reality Navigation Combined With Fluorescence Imaging for Colorectal Liver Metastases: A Retrospective Cohort Study Using Inverse Probability Treatment Weighting Analysis

Int J Surg. 2024 Dec 24. doi: 10.1097/JS9.0000000000002193. Online ahead of print.

Authors

Xiaojun Zeng^{1

2}, Xinci Li^{1

2}, Wenjun Lin^{1

2}, Junfeng Wang^{1

2}, Chihua Fang^{1

2}, Mingxin Pan^{1

2}, Haisu Tao^{1

2}, Jian Yang^{1

2}

Affiliations

¹ Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
² Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, China.

PMID: 39715148
DOI: 10.1097/JS9.0000000000002193

Abstract

Background: Laparoscopic parenchyma-sparing hepatectomy (PSH) is an effective treatment for colorectal liver metastases (CRLMs), but ensuring the safety and radicality of the procedure, particularly for deep-seated tumors, remains challenging. Surgical navigation technologies such as augmented reality navigation (ARN) and indocyanine green fluorescence imaging (ICG-FI) are increasingly utilized to guide surgery, yet their efficacy for CRLMs is unclear. This study aims to evaluate the short- and long-term outcomes of ARN combined with ICG-FI-guided (ARN-FI) laparoscopic PSH for CRLMs.

Methods: Between January 2020 and December 2022, eighty-nine consecutive patients who underwent laparoscopic PSH for CRLMs were included in the study. Patients were divided into ARN-FI group (n = 38) and non-ARN-FI group (n = 51) based on the use of ARN-FI. Inverse probability treatment weighting (IPTW) was used to balance baseline characteristics and minimize potential selection bias. Short-term and long-term outcomes were compared between the two groups. Cox regression analysis was conducted to identify risk factors associated with recurrence-free survival (RFS) and hepatic RFS.

Results: After IPTW, there were 87 patients in the ARN-FI group and 89 patients in the non-ARN-FI group. Shorter parenchymal transection time, postoperative hospital stays and wider margins were observed in the ARN-FI group. No significant difference in RFS or hepatic RFS between the groups. Mutant KRAS status was an independent risk factor for both RFS and hepatic RFS, while tumor diameter ≥ 5 cm and deep-seated location were risk factors for hepatic RFS. In the subgroup analysis of deep-seated tumors, the ARN-FI group also showed less intraoperative blood loss, a lower rate of strategy change, shorter postoperative recovery times, a higher R0 resection rate, and improved RFS and hepatic RFS.

Conclusions: In laparoscopic PSH for CRLMs, ARN-FI may improve surgical efficiency and accuracy. Especially for deep-seated tumors, it has the potential to reduce blood loss and attain higher R0 resection rates.